FIELD: biotechnology.
SUBSTANCE: group of inventions is described, including a non-viral capsidless DNA vector with covalently closed ends for nucleic acid delivery, an scDNA expression construct for producing a scDNA vector, a host cell producing an scDNA expression construct, a method of obtaining a scDNA vector, the use of a composition containing scDNA a vector for producing a medicinal product for delivering a therapeutic protein to a subject to correct an abnormal level and/or function of a gene product, a set for delivering a nucleic acid, and a set for producing a scDNA vector.
EFFECT: invention expands the arsenal of agents for delivering nucleic acids.
62 cl, 62 dwg, 17 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED CLOSED CIRCULAR DNA (CCDNA) CONTAINING SYMMETRIC MODIFIED INVERTED END REPEATED SEQUENCES | 2019 |
|
RU2816963C2 |
| MODULATION OF REP PROTEIN ACTIVITY WHEN PRODUCING CLOSED-END DNA (ceDNA) | 2020 |
|
RU2812850C2 |
| GENE EDITING USING MODIFIED CLOSED-END DNA (ceDNA) | 2018 |
|
RU2811724C2 |
| CLOSED-ENDED DNA VECTORS OBTAINED BY CELL-FREE SYNTHESIS, AND METHOD OF PRODUCING CEDNA VECTORS | 2019 |
|
RU2820586C2 |
| NON-VIRAL DNA VECTORS AND OPTIONS FOR THEIR USE FOR EXPRESSION OF THERAPEUTIC AGENT BASED ON PHENYLALANINE HYDROXYLASE (PAH) | 2020 |
|
RU2814137C2 |
| NON-VIRAL DNA VECTORS AND THEIR USE FOR THE PRODUCTION OF ANTIBODIES AND FUSION PROTEINS | 2019 |
|
RU2800914C2 |
| NON-VIRAL DNA VECTORS AND OPTIONS FOR THEIR USE FOR EXPRESSION OF THERAPEUTIC AGENT BASED ON FACTOR VIII (FVIII) | 2020 |
|
RU2812852C2 |
| MODULATING POLYNUCLEOTIDES | 2015 |
|
RU2749882C2 |
| MODULATING POLYNUCLEOTIDES | 2015 |
|
RU2719192C2 |
| CONTROLLED EXPRESSION OF TRANSGENES USING CLOSED-END DNA VECTORS (ceDNA) | 2019 |
|
RU2816871C2 |
